Prothrombotic consequences of the oxidation of fibrinogen and their inhibition by aspirin

Journal of Thrombosis and Thrombolysis

Volumn 5, Issue 1, 1998, Pages 9-14

  Upchurch Jr , Gilbert R ^a,b   Ramdev, Nomith ^a   Walsh, Mary T ^a   Loscalzo, Joseph ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Fibrinogen; Fibrinolysis; Platelets; Tissue type plasminogen activator

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FERROUS ASCORBATE; FIBRIN; FIBRINOGEN; LYSINE; PLASMA PROTEIN; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR;

ALPHA HELIX; ARTICLE; BLOOD CLOTTING; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG ACETYLATION; DRUG OXIDATION; FIBRINOLYSIS; HUMAN; OXIDATIVE STRESS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; THROMBOCYTE AGGREGATION;

EID: 6844252920     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008859729045     Document Type: Article

References (26)

1. Stadtman ER. Oxidation of free amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Ann Rev Biochem 1993;62:797-821.
2. Stadtman ER. Protein oxidation and aging. Science 1992;257: 1220-1224.
3. Stief TW, Marx R, Heimburger N. Oxidized fibrin(ogen) derivatives enhance the activity of tissue type plasminogen activator. Thromb Res 1989;56:221-228.
4. Shacter E, Williams JA, Lim M, Levine, L. Differential susceptibility of plasma proteins to oxidative modification: Examination by western blot immunoassay. Free Radic Biol Med 1994;7:429-437.
5. Witztum JL, Steinberg DL. Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-1792.
6. Rabbani LE, Loscalzo J. Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atherosclerosis 1994;105:1-7.
7. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: Principal result of the Northwick Park Heart Study. Lancet 1986;2:533-537.
8. Ridker PM, Hennekens CH. Hemostatic risk factors for coronary heart disease. Circulation 1991;83:1098-1100.
9. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320-331.
10. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary prevention of cardiovascular disease. Circulation 1989;80: 749-756.
11. Roth GH, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624-632.
12. 2-terminal serine of prostaglandin synthetase by aspirin. J Biol Chem 1978;253: 3782-3784.
13. 2, and prostacyclin. Pharmacol Rev 1979;30:293-331.
14. Hanson Sr, Harker LA, Bjornsson, TD. Effects of platelet modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J Clin Invest 1985;75: 1591-1599.
15. Bjornsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1989;250:154-161.
16. Ezratty A, Freedman JE, Simon D, Loscalzo J. The antithrombotic effects of acetylation of fibrinogen by aspirin. J Vasc Med Biol 1994;5:152-159.
17. Okonkwo P, Sise HS. Effect of aspirin in vivo and in vitro on plasma cofactors of platelet aggregation. Thromb Diath Haemorrk 1971;25:279-287.
18. Pinckard RN, Hawkins D, Farr RS. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature 1968; 219:68-69.
19. Greenfield N, Fasman GD. Computed circular dichroism spectra for the evaluation of protein conformation. Biochemistry 1969;10:4108-4116.
20. Mao D, Wallace BW. Differential light scattering and absorption flattening optical effects are minimal in the circular dichroism spectra of unilamellar vesicles. Biochemistry 1984; 23:2667-2673.
21. Chang CT, Wu C-SCC, Yang JT. Circular dichroic analysis of protein conformation: Inclusion of the β-turns. Anal Biochem 1978;91:13-31.
22. Brahms S, Brahms J. Determination of protein secondary structure in solution by vacuum ultraviolet circular dichroism. J Mol Biol 1980;138:149-178.
23. Sears DW, Beychok S. Circular Dichroism. In Leach SJ, ed. Physical Principles and Techniques of Protein Chemistry, Part C. New York: Academic Press,: 1993;445-593.
24. Ranby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982;704:461-469.
25. Budzynski AZ. Difference in conformation of fibrinogen degradation products as revealed by hydrogen exchange and spectropolarimetry. Biochim Biophys Acta 1971;229:663-671.
26. Mihalyi E. Physicochemical studies of bovine fibrinogen. III. Optimal rotation of the native and denatured molecule. Biochim Biophys Acta 1965;102:487-499.